QR Kodea

Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks

Abstract Background Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient-reported outcomes at weeks 16 and 52 in patients with moderate-to-severe atopic dermatitis (AD). We report the sustained impact of lebrikizumab monotherapy, over 52 weeks a...

Deskribapen osoa

Gorde:
Egile Nagusiak: Gil Yosipovitch, Peter Lio, Franz J. Legat, Raj Chovatiya, Mette Deleuran, Evangeline Pierce, Marta Casillas, Yuxin Ding, Fan E. Yang, Laia Bardolet, Sonja Ständer
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Adis, Springer Healthcare 2024-07-01
Saila:Dermatology and Therapy
Gaiak:
Atopic dermatitis
Itch
Lebrikizumab
Sleep
POEM
Sarrera elektronikoa:https://doi.org/10.1007/s13555-024-01225-w
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak